Imaging Mass Cytometry
Also known as: IMC, mass cytometry, multiplex ion beam imaging, MIBI
Imaging Mass Cytometry (IMC) is a multiplexed proteomics technique that maps the subcellular localization of up to 40-50 proteins in tissue sections simultaneously using mass spectrometry detection. Developed by Bodenmiller and colleagues in 2014, IMC combines the single-cell imaging power of immunofluorescence with the multiplexing capacity of mass cytometry, enabling comprehensive analysis of cell types, states, and spatial interactions within tissue microenvironments. IMC has emerged as a powerful tool in immuno-oncology, immunobiology, and tissue biology for dissecting cellular heterogeneity and spatial organization.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
IMC is indicated when comprehensive single-cell proteomic analysis with spatial context is required. Most developed in immuno-oncology (tumor microenvironment analysis, immunotherapy response prediction) and inflammatory diseases (autoimmunity, infection). IMC requires fresh or well-preserved frozen/formalin-fixed tissue, a validated antibody panel, and specialized instrumentation (Fluidigm Helios or other IMC platforms). IMC is complementary to flow cytometry (more markers in suspension, no spatial context) and spatial transcriptomics (RNA instead of protein, different resolution).
Strengths & limitations
- High multiplexing: 40-50+ protein markers simultaneously detected, far exceeding immunofluorescence (3-5) and approaching flow cytometry (20-30) capacity
- Single-cell resolution: subcellular localization (~1 micrometer) reveals spatial protein distribution within cells (cytoplasm vs nucleus vs membrane)
- Spatial context preservation: unlike dissociated single-cell methods, tissue architecture and cell-cell interactions are maintained
- Quantitative: signal intensity is proportional to protein abundance, enabling quantitative comparison across conditions and validation of biology
- Minimal technical variability: lanthanide tags have no spectral overlap, eliminating compensation and cross-talk issues of fluorescence
- Limited throughput: Helios instrument ablates ~10-100 cell equivalents per second; imaging a 5 mm² tissue requires hours; whole-tissue scans are time-prohibitive
- Antibody availability: not all proteins have commercially available lanthanide-conjugated antibodies; custom conjugation is expensive and time-consuming
- Batch variability: staining, ablation, and detection can vary batch-to-batch; normalization strategies are still being refined
- Protein detection bias: heavy metals (lanthanides) can quench fluorescence and affect antibody staining; some protein-antibody combinations may not work in IMC
- Cost: instrumentation, antibodies, and analysis expertise are expensive; limiting adoption to well-resourced institutions
Frequently asked
How many proteins can be detected in a single IMC experiment?
Current Helios instruments detect 40-50 protein markers simultaneously per experiment. Lanthanide isotopes span a wide mass range (130-160 m/z and 165-209 m/z), but only ~40 are practically exploitable after accounting for isotope overlap and interference. Larger panels are being developed; some emerging platforms claim 100+ channels. Protein selection should prioritize biologically relevant markers (cell type, activation, migration, apoptosis) over comprehensive profiling.
What tissue types are compatible with IMC, and how should they be prepared?
IMC works on formalin-fixed paraffin-embedded (FFPE) tissue (most common), snap-frozen sections, and fresh tissue. FFPE is preferred for clinical samples due to stability and archival compatibility. Sections should be 5-10 micrometers thick, cut on charged slides, and baked at 60-80°C to improve adhesion. Antigen retrieval is often necessary for FFPE; protocols vary by antibody. Tissue quality is critical; heavily autofluorescent or damaged tissue degrades signal.
How do I design an antibody panel for IMC?
Panel design should balance biological hypothesis (e.g., T cell exhaustion markers, fibroblast subtypes) with practical considerations: (1) Validate antibodies in flow cytometry or immunofluorescence first; (2) Distribute isotopes across mass range to minimize interference; (3) Include positive and negative controls (e.g., common markers with high and low expression); (4) Reserve a few channels for imaging quality control (histone H3, DNA); (5) Prioritize unique markers over redundancy. Most published panels have 30-40 markers; larger panels require careful isotope balancing.
How do I handle missing data or dropout channels in IMC?
Complete dropout (no signal in a channel) can indicate antibody staining failure, optical issues, or isotope interference. Partial dropout (signal in only a subset of cells) may indicate true biology (marker not expressed in all cells) or staining heterogeneity. Before excluding a channel, verify: (1) Positive control samples stain correctly; (2) Antibody concentration and incubation time are appropriate; (3) No mass-to-charge interference from neighboring isotopes. If problems persist, re-stain with a freshly conjugated antibody. Complete dropout channels should be excluded from analysis.
What is the difference between IMC and spatial transcriptomics, and should I use both?
IMC measures proteins at single-cell resolution with ~1 micrometer spatial accuracy. Spatial transcriptomics (Visium, MERFISH, seqFISH) measures RNA, usually at lower spatial resolution (Visium: 55 micrometers/spot) or higher cost/complexity (seqFISH: 1-10 micrometers but 30-50 genes per run). Proteins are more stable, easier to multiplex, and more directly linked to function; RNA profiles are more comprehensive but less immediately functional. Ideally, use both: IMC for immune and stromal protein phenotyping; spatial transcriptomics for tumor cell genotyping or genome-wide signatures.
Sources
- Giesen, C., Wang, H. A., Schapiro, D., et al. (2014). Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nature Methods, 11(4), 417-422. DOI: 10.1038/nmeth.2869 ↗
- Jackson, H. W., Fischer, J. R., Zanotelli, V. R., et al. (2020). The single-cell pathology of synovial inflammation in rheumatoid arthritis. Nature Medicine, 26(6), 941-951. link ↗
- Schulz, D., Zanotelli, V. R., Fischer, J. R., et al. (2018). Simultaneous multiplexed imaging of mRNA and proteins with subcellular resolution in breast cancer tissue samples by imaging mass cytometry. Nature Protocols, 13(12), 2825-2848. DOI: 10.1016/j.cels.2018.04.004 ↗
How to cite this page
ScholarGate. (2026, June 3). Imaging Mass Cytometry. ScholarGate. https://scholargate.app/en/medical-imaging/imaging-mass-cytometry
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Functional UltrasoundMedical Imaging↔ compare
- OCT AngiographyMedical Imaging↔ compare
- PET Kinetic ModelingMedical Imaging↔ compare
- Quantitative Susceptibility MappingMedical Imaging↔ compare
- RadiomicsMedical Imaging↔ compare